Health & bio
NIH: oral small-molecule GLP-1 penetrates brain; suppresses cravings
Oral small-molecule GLP-1 drugs cross the blood-brain barrier to inhibit cravings, representing a next-generation obesity pharmacology candidate.
Primary sources · 1
Oral small-molecule GLP-1 drugs cross the blood-brain barrier to inhibit cravings, representing a next-generation obesity pharmacology candidate.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.